Fatal laryngeal angioedema: a case report and a workup of angioedema in a forensic setting

Forensic Science, Medicine, and Pathology

Volumn 11, Issue 4, 2015, Pages 558-563

  Krizova, Adriana ^a,b,c   Gardner, Taylor ^a   Little, D’Arcy L ^a,b   Arcieri Piersanti, V ^a   Pollanen, Michael S ^a,b  

^a Ontario Forensic Pathology Service   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

ACEI induced angioedema; Angioedema; Angioedema workup in forensic pathology; Drug induced angioedema; Postmortem CT of angioedema

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AIRWAY OBSTRUCTION; ANGIONEUROTIC EDEMA; CASE REPORT; CHEMICALLY INDUCED; FATALITY; HUMAN; LARYNX DISORDER; MALE; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY;

AIRWAY OBSTRUCTION; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FATAL OUTCOME; HUMANS; LARYNGEAL DISEASES; MALE; MIDDLE AGED;

EID: 84947492223     PISSN: 1547769X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12024-015-9701-9     Document Type: Article

References (46)

1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.
2. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy. 2014;69:602–16.
3. McLean-Tooke A, Goulding M, Bundell C, White J, Hollingsworth P. Postmortem serum tryptase levels in anaphylactic and non-anaphylactic deaths. J Clin Pathol. 2014;67:134–8.
4. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380–4.
5. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol. 2000;106:65–71.
6. Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol. 2012;160:192–9.
7. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J Forensic Sci. 1995;40:208–11.
8. Edston E, Eriksson O, van Hage M. Mast cell tryptase in postmortem serum-reference values and confounders. Int J Legal Med. 2007;121:275–80.
9. Edston E, van Hage-Hamsten M. Mast cell tryptase and haemolysis after trauma. Forensic Sci Int. 2003;131:8–13.
10. Fineschi V, Cecchi R, Centini F, Reattelli LP, Turillazzi E. Immunohistochemical quantification of pulmonary mast-cells and postmortem blood dosages of tryptase and eosinophil cationic protein in 48 heroin-related deaths. Forensic Sci Int. 2001;120:189–94.
11. Ishigami K, Averill SL, Pollard JH, McDonald JM, Sato Y. Radiologic manifestations of angioedema. Insights Imaging. 2014;5:365–74.
12. Ogasawara T, Kitagawa Y, Ogawa T, Yamada T, Kawamura Y, Sano K. MR imaging and thermography of facial angioedema: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:473–6.
13. Bafunno V, Divella C, Sessa F, Tiscia GL, Castellano G, Gesualdo L, et al. De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. J Allergy Clin Immunol. 2013;132:748–50.
14. Blanch A, Roche O, Urrutia I, Gamboa P, Fontán G, López-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol. 2006;118:1330–5.
15. López-Lera A, Favier B, de la Cruz RM, Garrido S, Drouet C, López-Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol. 2010;126:1307–10.
16. Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet. 2006;79:1098–104.
17. Bork K, Gül D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120:987–92.
18. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129–34.
19. Mandle R, Baron C, Roux E, Sundel R, Gelfand J, Aulak K, et al. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994;152:4680–5.
20. Jackson J, Feighery C. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med. 1988;318:122–3.
21. Castelli R, Deliliers DL, Zingale LC, Pogliani EM, Cicardi M. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica. 2007;92:716–8.
22. Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006;119:e3–5.
23. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med. 1987;316:1360–6.
24. Donaldson VH, Bernstein DI, Wagner CJ, Mitchell BH, Scinto J, Bernstein IL. Angioneurotic edema with acquired C1-inhibitor deficiency and autoantibody to C1-inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med. 1992;119:397–406.
25. Branellec A, Bouillet L, Javaud N, Mekinian A, Boccon-Gibod I, Blanchard-Delaunay C, et al. Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol. 2012;32:936–41.
26. Inomata N. Recent advances in drug-induced angioedema. Allergol Int. 2012;61:545–57.
27. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126:400–4.
28. Garcia-Pavia P, Tomas JM, Alonso-Pulpon L. Late-onset angioedema due to an angiotensin-converting enzyme inhibitor. Can J Cardiol. 2007;23:315–6.
29. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967–70.
30. Guo X, Dick L. Late onset angiotensin-converting enzyme induced angioedema: case report and review of the literature. J Okla State Med Assoc. 1999;92:71–3.
31. Schiller PI, Messmer SL, Haefeli WE, Schlienger RG, Bircher AJ. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy. 1997;52:432–5.
32. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51–131.
33. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495–9.
34. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599–606.
35. Lin RY, Cannon AG, Teitel AD. Pattern of hospitalizations for angioedema in New York between 1990 and 2003. Ann Allergy Asthma Immunol. 2005;95:159–66.
36. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci. 2001;46:1239–43.
37. Cupido C, Rayner B. Life-threatening angio-oedema and death associated with the ACE inhibitor enalapril. S Afr Med J. 2007;97:244–5.
38. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608–9.
39. Abbosh J, Anderson JA, Levine AB, Kupin WL. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol. 1999;82:473–6.
40. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10:499–509.
41. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637–42.
42. Blais C Jr, Marc-Aurèle J, Simmons WH, Loute G, Thibault P, Skidgel RA, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides. 1999;20:421–30.
43. Cyr M, Hume HA, Champagne M, Sweeney JD, Blais C Jr, Gervais N, et al. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion. 1999;39(10):1084–8.
44. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088–9.
45. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005;77:617–26.
46. Grover C. Images in clinical medicine. “Thumb Sign” of epiglottitis. N Engl J Med. 2011;365:447.